Splenectomy as Flow Modulation Strategy and Risk Factors of De Novo Portal Vein Thrombosis in Adult‐to‐Adult Living Donor Liver Transplantation
Toru Ikegami, Tomoharu Yoshizumi, Norifumi Harimoto, Masaki Mori – 20 May 2019
Toru Ikegami, Tomoharu Yoshizumi, Norifumi Harimoto, Masaki Mori – 20 May 2019
Natalie J. Torok – 20 May 2019
Marina Serper, David E. Kaplan, Justine Shults, Peter P. Reese, Lauren A. Beste, Tamar H. Taddei, Rachel M. Werner – 20 May 2019 – Decompensated cirrhosis is associated with high morbidity and mortality. However, no standardized quality measures (QMs) have yet been adopted widely.
Joanne A. Hoogerland, Yu Lei, Justina C. Wolters, Jan Freark Boer, Trijnie Bos, Aycha Bleeker, Niels L. Mulder, Theo H. Dijk, Jan A. Kuivenhoven, Fabienne Rajas, Gilles Mithieux, Rebecca A. Haeusler, Henkjan J. Verkade, Vincent W. Bloks, Folkert Kuipers, Maaike H. Oosterveer – 18 May 2019 – It is well established that, besides facilitating lipid absorption, bile acids act as signaling molecules that modulate glucose and lipid metabolism. Bile acid metabolism, in turn, is controlled by several nutrient‐sensitive transcription factors.
Natalia Riva, Jean‐Baptiste Woillard, Maximiliano Distefano, Matias Moragas, Marcelo Dip, Esteban Halac, Paulo Cáceres Guido, Nieves Licciardone, Andrea Mangano, Andrea Bosaleh, María Teresa Davila, Paula Schaiquevich, Oscar Imventarza – 18 May 2019 – Tacrolimus is the cornerstone in pediatric liver transplant immunosuppression. Despite close monitoring, fluctuations in tacrolimus blood levels affect safety and efficacy of immunosuppressive treatments. Identifying the factors related to the variability in tacrolimus exposure may be helpful in tailoring the dose.
Jorge Mallea, Candice Bolan, Cherise Cortese, Denise Harnois – 18 May 2019 – Cystic fibrosis (CF) is an autosomal recessive disease characterized by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR gene mutations manifest as epithelial cell dysfunction in the airways, biliary tract, pancreas, gut, sweat glands, paranasal sinuses, and genitourinary tract.
Pijun Wang, Wen‐Jun Wang, Jo Choi‐Nurvitadhi, Yaniuska Lescaille, John W. Murray, Allan W. Wolkoff – 18 May 2019 – Organic anion transport proteins (OATPs) on the basolateral surface of hepatocytes mediate uptake of a number of drugs and endogenous compounds. Previous studies showed that rat OATP1A1 (rOATP1A1) has a postsynaptic density protein, drosophila disc large tumor suppressor, zonula occludens‐1 protein (PDZ) consensus binding motif at its C‐terminus and binds to PDZ domain containing 1 (PDZK1), which is required for its cell‐surface localization.
Nastaran Fazel Modares, Robin Polz, Fereshteh Haghighi, Larissa Lamertz, Kristina Behnke, Yuan Zhuang, Claus Kordes, Dieter Häussinger, Ursula R. Sorg, Klaus Pfeffer, Doreen M. Floss, Jens M. Moll, Roland P. Piekorz, M. Reza Ahmadian, Philipp A. Lang, Jürgen Scheller – 17 May 2019 – Interleukin‐6 (IL‐6) is critically involved in liver regeneration after partial hepatectomy (PHX). Previous reports suggest that IL‐6 trans‐signaling through the soluble IL‐6/IL‐6R complex is involved in this process.
Susan M. Siew, Sharon C. Cunningham, Erhua Zhu, Szun S. Tay, Elena Venuti, Christine Bolitho, Ian E. Alexander – 17 May 2019 – Recombinant adeno‐associated viral (rAAV) vectors are highly promising vehicles for liver‐targeted gene transfer, with therapeutic efficacy demonstrated in preclinical models and clinical trials. Progressive familial intrahepatic cholestasis type 3 (PFIC3), an inherited juvenile‐onset, cholestatic liver disease caused by homozygous mutation of the ABCB4 gene, may be a promising candidate for rAAV‐mediated liver‐targeted gene therapy.
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte – 17 May 2019 – Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases.